// App-Quantinova.ai

P5-11-17 : Phase IIIb CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2- advanced breast cancer (ABC): Interim results from the UK cohort

Researchers

Presenter

  • Alistair Ring

Principal Investigators

  • Timothy Crook

  • Mark Tuthill

  • Rebecca Roylance

  • Trevor McGoldrick

  • Stephen Chan

  • Helen Lo'Monte

  • William Roberts

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom

  • Oxford Respiratory Trials Unit, Oxford University Hospital NHS Trust, Oxford, United Kingdom,

  • University College London Hospitals NHS Foundation Trust, & NIHR University College London, London, United Kingdom

  • Statistics Group, University of Aberdeen, Aberdeen, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • Novartis Pharmaceuticals UK Ltd., Surrey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Ribociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • NCT02941926

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved